Health Care Delivery

Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.

Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.

People with multiple sclerosis make up most of a survey linking variable-friction footwear to fewer self-reported falls.

Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.

Nathan Estrada, DPT, explains which patients, including those with multiple sclerosis, may benefit from footwear that adapts to gait.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers

Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.

Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.

HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to costly oncology drugs.

Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.

Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

Universal HCV testing, community-based prevention, and peer navigators can help curb a decade-long surge in new US hepatitis C cases.

At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.